ChemicalBook > CAS DataBase List > BENZIMIDAVIR

BENZIMIDAVIR

Product Name
BENZIMIDAVIR
CAS No.
176161-24-3
Chemical Name
BENZIMIDAVIR
Synonyms
Maribavir;1263W94;Maribavi;Malibawei;Malibave.;BW 1263W94;GW 257406X;BENZIMIDAVIR;Maribavir Impurity Crystal-Free Type VI;5,6-DICHLORO-2-ISOPROPYLAMINO-1-(-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE
CBNumber
CB6375292
Molecular Formula
C15H19Cl2N3O4
Formula Weight
376.24
MOL File
176161-24-3.mol
More
Less

BENZIMIDAVIR Property

Boiling point:
611.0±65.0 °C(Predicted)
Density 
1.67±0.1 g/cm3 (20 ºC 760 Torr)
storage temp. 
2-8°C(protect from light)
solubility 
Soluble in DMSO
form 
Powder
pka
13.20±0.70(Predicted)
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML2941
Product name
Maribavir
Purity
≥98% (HPLC)
Packaging
5MG
Price
$118
Updated
2024/03/01
Sigma-Aldrich
Product number
SML2941
Product name
Maribavir
Purity
≥98% (HPLC)
Packaging
25MG
Price
$476
Updated
2024/03/01
ApexBio Technology
Product number
B3517
Product name
Maribavir
Packaging
10mg
Price
$551
Updated
2021/12/16
American Custom Chemicals Corporation
Product number
API0004838
Product name
MARIBAVIR
Purity
95.00%
Packaging
5MG
Price
$660
Updated
2021/12/16
ApexBio Technology
Product number
B3517
Product name
Maribavir
Packaging
5mg
Price
$347
Updated
2021/12/16
More
Less

BENZIMIDAVIR Chemical Properties,Usage,Production

Description

Maribavir is an orally bioavailable benzimidazole L-riboside antiviral, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein–Barr virus (EBV). It is an inhibitor of the CMV UL97 kinase. As of 2008, maribavir was in phase III clinical trials for prevention of CMV infection in transplant recipients at risk. Earlier phase I and II trials of maribavir showed anti-CMV activity with an acceptable adverse effect profile. Investigational drug code names include 1263W94, BW1263-W94, GW257406X, and VP41263, reflecting changes in ownership during drug development. As of early 2009, the drug was being developed under ‘‘fast track’’ status granted by the US Food and Drug Administration, but the apparent failure of maribar prophylaxis to prevent CMV infection in stem cell transplant recipients in the definitive phase III clinical trial resulted in the sponsor halting ongoing clinical development.

Uses

Treatment of cytomegalovirus infections (antiviral).

Mechanism of action

Maribavir inhibits the CMV UL97 kinase, an enzyme which is required for the normal replication of the virus . In the absence of functioning UL97 kinase, viral replication is severely impaired in vitro, with an abnormal cell culture cytopathic effect characterized by the nuclear aggregation of excess amorphous viral proteins, mainly the tegument protein pp65. Impaired UL97 function appears to cause a defect in viral encapsidation and/or egress of viral particles from the nucleus. In addition, viral DNA synthesis may also be reduced. CMV replication is not completely shut off in the absence of the UL97 kinase; the widely varying maribavir IC50s under different assay conditions suggest that host cells can variably substitute for the normal function of UL97, a factor that may affect the therapeutic potency of maribavir in vivo.

Drug interactions

Since CYP3A4 appears to be the major maribavir-metabolizing enzyme, there are potential drug interactions with CYP3A4 inhibitors, such as azole antifungals, macrolide antibiotics, and HIV protease inhibitors, or CYP3A4 inducers, such as rifampicin or efavirenz. There are insufficient data to assess the clinical significance of this interaction. Phase I clinical trials examined the pharmacokinetics of maribavir in HIV-infected subjects, many of whom were concomitantly using antifungals and protease inhibitors. Overall, the pharmacokinetic data were not significantly different from those of healthy individuals not on these drugs. In healthy adults, oral administration of ketoconazole, a potent CYP3A4 inhibitor, resulted in a 35% decrease in the clearance of maribavir, which is not expected to have adverse consequences because of the low observed toxicity of maribavir. Further studies are required to assess potential impairment of antiviral activity by CYP3A4 inducers. Maribavir may have some inhibitory effect on cytochrome P450 isozymes, CYP2C19 and CYP2D6, as assessed after administration of multiple concurrently administered drug probes, including omeprazole (2C19) and dextromethorphan (2D6).

BENZIMIDAVIR Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

BENZIMIDAVIR Suppliers

LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
Musechem
Tel
+1-800-259-7612
Fax
+1-800-259-7612
Email
info@musechem.com
Country
United States
ProdList
4660
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32161
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Alchem Pharmtech,Inc.
Tel
8485655694
Email
sales@alchempharmtech.com
Country
United States
ProdList
63687
Advantage
58
Protheragen-ING
Tel
+16313385890
Email
info@protheragen-ing.com
Country
United States
ProdList
3868
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
AlliChem, LLC
Tel
--
Fax
--
Email
sales@allichemllc.com
Country
United States
ProdList
6516
Advantage
60
2A PharmaChem USA
Tel
--
Fax
--
Email
sales@2apharmachem.com
Country
United States
ProdList
6137
Advantage
39
3B Scientific Corporation
Tel
--
Fax
--
Email
sales@3bsc.com
Country
United States
ProdList
6718
Advantage
47
APAC Pharmaceutical, LLC
Tel
--
Fax
--
Email
sales@apacpharma.com
Country
United States
ProdList
6322
Advantage
38
ChemPacific Corporation
Tel
--
Fax
--
Email
sales@chempacific.com
Country
United States
ProdList
6891
Advantage
51
BOSCHE SCIENTIFIC, LLC
Tel
--
Fax
--
Email
Sales@BoscheSci.com
Country
United States
ProdList
6477
Advantage
55

176161-24-3, BENZIMIDAVIRRelated Search:


  • Maribavi
  • 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE
  • BENZIMIDAVIR
  • BENZIMIDAVIR, 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(β-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE
  • 5,6-DICHLORO-2-ISOPROPYLAMINO-1-(-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE
  • BENZIMIDAVIR: 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(SS-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE
  • (2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetr
  • Maribavir
  • 1263W94
  • 5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine
  • BW 1263W94
  • GW 257406X
  • (2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
  • (2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)t
  • 1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-β-L-ribofuranosyl-
  • Malibawei
  • Malibave.
  • Maribavir Impurity Crystal-Free Type VI
  • 176161-24-3
  • 76161-24-3
  • C15H19Cl2N3O4
  • Inhibitors